- Conditions
- Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
- Interventions
- BGJ398
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,582
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Interstitial Cystitis
- Interventions
- Liposomes
- Drug
- Lead sponsor
- Kenneth Peters, MD
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
- Interventions
- Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer
- Interventions
- CDX-1307 Vaccine Regimen, Chemotherapy
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 13 more
- Conditions
- Urinary Retention, Neurogenic Bladder, Urologic Diseases
- Interventions
- Connected Urinary Catheter
- Device
- Lead sponsor
- Spinal Singularity
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Downey, California • Inglewood, California • Murrieta, California + 6 more
- Conditions
- Vesicoureteral Reflux
- Interventions
- Anti-reflux surgery, Endoscopic injection
- Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 11 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Locally Advanced or Metastatic Solid Tumor(s), Prostate Cancer, Esophageal Cancer, Triple Negative Breast Cancer (TNBC), Squamous Cell Carcinoma of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Bladder Cancer, Uterine Cancer
- Interventions
- GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Houston, Texas
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 900 participants
- Timeline
- 2016 – 2029
- U.S. locations
- 6
- States / cities
- Long Beach, California • Los Angeles, California • Newport Beach, California + 2 more
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Zinc Citrate Oral Capsule, Placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 21 Years to 100 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Skokie, Illinois
- Conditions
- Urinary Retention, Neurogenic Bladder
- Interventions
- An intermittent urethral urinary catheter with a tip, tube and drainage eyelets
- Device
- Lead sponsor
- Hollister Incorporated
- Industry
- Eligibility
- 22 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Libertyville, Illinois
- Conditions
- Overactive Bladder
- Interventions
- fesoterodine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Female Sexual Dysfunction, Overactive Bladder
- Interventions
- Anticholinergic, PTNS
- Drug · Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana • Louisville, Kentucky + 2 more
- Conditions
- Bladder Cancer
- Interventions
- Apaziquone, Placebo
- Drug · Other
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Overactive Bladder, Urinary Incontinence
- Interventions
- Botox
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Interventions
- UGN-301, UGN-201, Gemcitabine
- Drug
- Lead sponsor
- UroGen Pharma Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
- Conditions
- Overactive Bladder
- Interventions
- Hydrodistention, Botulinum toxin-A
- Procedure · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,063 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Bladder Cancer, Hematuria
- Interventions
- AssureMDx
- Diagnostic Test
- Lead sponsor
- MDx Health
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 1,148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
- Interventions
- Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support
- Behavioral
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
- Interventions
- sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,006 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 106
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more
- Conditions
- Overactive Bladder
- Interventions
- SSR240600C, Placebo, Tolterodine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Interventions
- Vepugratinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Myrtle Beach, South Carolina
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Melanoma, Ovarian Cancer, Adrenocortical Cancer, Breast Cancer, Other Cancer
- Interventions
- Not listed
- Lead sponsor
- Quantgene Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Celebration, Florida • Orlando, Florida + 2 more